Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity

Neoantigen burden is a major determinant of tumor immunogenicity, underscored by recent clinical experience with checkpoint blockade therapy. Yet the majority of patients do not express, or express too few, neoantigens, and hence are less responsive to immune therapy. Here we describe an approach wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Garrido, Greta, Schrand, Brett, Rabasa, Ailem, Levay, Agata, D’Eramo, Francesca, Berezhnoy, Alexey, Modi, Shrey, Gefen, Tal, Marijt, Koen, Doorduijn, Elien, Dudeja, Vikas, van Hall, Thorbald, Gilboa, Eli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704146/
https://www.ncbi.nlm.nih.gov/pubmed/31434881
http://dx.doi.org/10.1038/s41467-019-11728-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704146/
https://www.ncbi.nlm.nih.gov/pubmed/31434881
http://dx.doi.org/10.1038/s41467-019-11728-2

Ejemplares similares